Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
September 2016, Vol 7, No 8
September 2016, Vol 7, No 8
Baseline BMD Testing Suboptimal in Older Women with Breast Cancer Starting Aromatase Inhibitor Therapy
By
Alice Goodman
Breast Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Approximately 33% of older women with early-stage breast cancer are not being tested for bone mineral density (BMD) before starting aromatase inhibitor therapy, according to a new and to date the largest population-based study on this topic (Charlson J, et al.
J Natl Compr Canc Netw
. 2016;14:875-880).
Read Article
Changes in Patient-Reported Outcomes Linked to Better Survival in Metastatic Prostate Cancer
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Patient-reported outcomes had significant associations with survival in metastatic castration-resistant prostate cancer (mCRPC), suggesting potential implications for clinical management, reported Tomasz M. Beer, MD, Oregon Health & Science University, Knight Cancer Institute, Portland, and colleagues, at the 2016 International Society for Pharmacoeconomics and Outcomes Research annual meeting.
Read Article
Rise in Metastatic Prostate Cancer Has Screening, Treatment Implications
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
The incidence of metastatic prostate cancer increased by >70% from 2004 to 2013, including >90% in the age-group most likely to benefit from definitive treatment, according to a new analysis of a national database (Weiner AB, et al.
Prostate Cancer Prostatic Dis
. 2016 Jul 19. Epub ahead of print).
Read Article
Clinical Pathways in Payment Reform Should Address Risk Adjustment
By
Chase Doyle
Clinical Pathways
September 2016, Vol 7, No 8
It does not take a crystal ball, or even an economist, to foretell that disaster is imminent in the healthcare system if premiums and out-of-pocket costs continue to rise, along with the cost of cancer drugs. Although the government attempts to rectify the situation with Medicare payment reform, new payment and care delivery models, such as the Oncology Care Model (OCM) pilot, and laws, such as the 2015 Medicare Access and CHIP Reauthorization Act (MACRA), present financial challenges for oncologists.
Read Article
FDA News - September 2016
September 2016, Vol 7, No 8
Read Article
In the Literature - September 2016
In the Literature
September 2016, Vol 7, No 8
Read Article
Guidelines and Pathway: Link to Benefit Design by Employers
By
Kristin Jarrell, PharmD
;
Michael Toscani, PharmD
Employers’ Perspective
,
Value Peer-spectives
September 2016, Vol 7, No 8
In today’s changing oncology landscape, the quality and value of cancer care have become increasingly integrated. With the rising costs of cancer treatment, payers and policymakers aim to better define value, as well as to educate patients about their therapeutic options. Insurers and payers have implemented a variety of strategies to control costs at the behest of employer plan sponsors, including utilizing oncology clinical pathways.
Read Article
Referring Radical Prostatectomies to High-Volume Providers Could Save Millions
By
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
A new study of the geographic distribution of cancer surgeries in the Medicare population has shown that performing radical prostatectomies in high-volume centers leads to improved outcomes and reduced costs of care. Referring patients to a high-volume provider within 100 miles could save >$20 million annually, according to data presented at the 2016 American Society of Clinical Oncology annual meeting and published just before the meeting.
Read Article
Assessing the Cost–Benefit of Immune Checkpoint Inhibitors
By
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
Although immune checkpoint inhibitors can significantly extend survival of patients with metastatic disease, more than 50% of the patients who use them have serious, grade 3 to grade 5 adverse events. These toxicities comprise a considerable proportion of the total number of immune checkpoint inhibitors, especially those that target PD-1, said Neil T. Mason, MBA, Personalized Medicine Strategist, Moffitt Cancer Center, Tampa, FL, who presented his study results at a poster session at the 2016 American Society of Clinical Oncology annual meeting.
Read Article
Concurrent Radiation and Temozolomide Lowers Risk for Death in Elderly Patients with Glioblastoma
By
Walter Alexander
Brain Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
The first study to assess the addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance of temozolomide in elderly patients with glioblastoma showed a significantly reduced risk for death, said the study co-author James R. Perry, MD, FRCPC, The Crolla Family Endowed Chair in Brain Tumour Research, Odette Cancer and Sunnybrook Health Sciences Centres, Toronto, Canada, in a plenary session at the 2016 American Society of Clinical Oncology annual meeting.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma